Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Thompson Investment Management Inc.

Thompson Investment Management Inc. boosted its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 17.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 241,774 shares of the medical research company's stock after acquiring an additional 36,505 shares during the quarter. Exact Sciences accounts for 2.0% of Thompson Investment Management Inc.'s investment portfolio, making the stock its 6th biggest position. Thompson Investment Management Inc. owned 0.13% of Exact Sciences worth $13,585,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Huntington National Bank boosted its stake in Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after acquiring an additional 352 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in shares of Exact Sciences in the 3rd quarter worth $34,000. Capital Performance Advisors LLP bought a new position in shares of Exact Sciences during the 3rd quarter valued at about $35,000. Modus Advisors LLC bought a new position in shares of Exact Sciences in the fourth quarter valued at $43,000. Finally, Vestor Capital LLC purchased a new stake in shares of Exact Sciences during the third quarter valued at $46,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

Exact Sciences Stock Performance

Shares of EXAS stock traded down $0.72 during trading hours on Wednesday, reaching $50.34. The company had a trading volume of 1,426,910 shares, compared to its average volume of 2,150,925. The firm has a market cap of $9.32 billion, a PE ratio of -43.03 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The business has a fifty day moving average price of $56.66 and a 200-day moving average price of $60.13.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of research analyst reports. The Goldman Sachs Group lowered their price target on Exact Sciences from $75.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Stifel Nicolaus reduced their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. TD Cowen increased their price target on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Evercore ISI dropped their price target on Exact Sciences from $80.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group reduced their target price on shares of Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $72.76.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.